Boehringer wins accelerated approval for first-line use of lung cancer drugnews2026-02-26T20:03:47+00:00February 26th, 2026|Endpoints News|
Senate hearing raises FDA-related concerns for new rare disease drugsnews2026-02-26T19:27:02+00:00February 26th, 2026|Endpoints News|
HHS commits up to $144M to study anti-aging approaches via ARPA-Hnews2026-02-24T20:46:28+00:00February 24th, 2026|Endpoints News|
Patient dies in MacroGenics’ cancer study, FDA puts trial on holdnews2026-02-24T15:40:28+00:00February 24th, 2026|Endpoints News|
Immedica wins accelerated approval for once-rejected rare disease drugnews2026-02-24T14:18:23+00:00February 24th, 2026|Endpoints News|
Fortress to sell priority review voucher for $205Mnews2026-02-23T19:34:21+00:00February 23rd, 2026|Endpoints News|
FDA unveils long-awaited guidance on new pathway for individualized therapiesnews2026-02-23T16:30:45+00:00February 23rd, 2026|Endpoints News|
Vanda gets FDA approval for ‘franchise-extending’ antipsychoticnews2026-02-21T00:51:50+00:00February 21st, 2026|Endpoints News|
Teva beats Corcept in appeals fight over generic Cushing’s syndrome drugnews2026-02-19T19:08:40+00:00February 19th, 2026|Endpoints News|
FDA formalizes one pivotal trial policy via NEJM perspectivenews2026-02-19T16:47:54+00:00February 19th, 2026|Endpoints News|
